486 related articles for article (PubMed ID: 27457036)
1. Short- and long-term effects of neonatal pharmacotherapy with epigallocatechin-3-gallate on hippocampal development in the Ts65Dn mouse model of Down syndrome.
Stagni F; Giacomini A; Emili M; Trazzi S; Guidi S; Sassi M; Ciani E; Rimondini R; Bartesaghi R
Neuroscience; 2016 Oct; 333():277-301. PubMed ID: 27457036
[TBL] [Abstract][Full Text] [Related]
2. A flavonoid agonist of the TrkB receptor for BDNF improves hippocampal neurogenesis and hippocampus-dependent memory in the Ts65Dn mouse model of DS.
Stagni F; Giacomini A; Guidi S; Emili M; Uguagliati B; Salvalai ME; Bortolotto V; Grilli M; Rimondini R; Bartesaghi R
Exp Neurol; 2017 Dec; 298(Pt A):79-96. PubMed ID: 28882412
[TBL] [Abstract][Full Text] [Related]
3. Long-term effect of neonatal inhibition of APP gamma-secretase on hippocampal development in the Ts65Dn mouse model of Down syndrome.
Stagni F; Raspanti A; Giacomini A; Guidi S; Emili M; Ciani E; Giuliani A; Bighinati A; Calzà L; Magistretti J; Bartesaghi R
Neurobiol Dis; 2017 Jul; 103():11-23. PubMed ID: 28359846
[TBL] [Abstract][Full Text] [Related]
4. Long-term effects of neonatal treatment with fluoxetine on cognitive performance in Ts65Dn mice.
Stagni F; Giacomini A; Guidi S; Ciani E; Ragazzi E; Filonzi M; De Iasio R; Rimondini R; Bartesaghi R
Neurobiol Dis; 2015 Feb; 74():204-18. PubMed ID: 25497735
[TBL] [Abstract][Full Text] [Related]
5. Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of Down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes.
Stringer M; Abeysekera I; Thomas J; LaCombe J; Stancombe K; Stewart RJ; Dria KJ; Wallace JM; Goodlett CR; Roper RJ
Physiol Behav; 2017 Aug; 177():230-241. PubMed ID: 28478033
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of APP gamma-secretase restores Sonic Hedgehog signaling and neurogenesis in the Ts65Dn mouse model of Down syndrome.
Giacomini A; Stagni F; Trazzi S; Guidi S; Emili M; Brigham E; Ciani E; Bartesaghi R
Neurobiol Dis; 2015 Oct; 82():385-396. PubMed ID: 26254735
[TBL] [Abstract][Full Text] [Related]
7. Treatment with corn oil improves neurogenesis and cognitive performance in the Ts65Dn mouse model of Down syndrome.
Giacomini A; Stagni F; Emili M; Guidi S; Salvalai ME; Grilli M; Vidal-Sanchez V; Martinez-Cué C; Bartesaghi R
Brain Res Bull; 2018 Jun; 140():378-391. PubMed ID: 29935232
[TBL] [Abstract][Full Text] [Related]
8. Pharmacotherapy with fluoxetine restores functional connectivity from the dentate gyrus to field CA3 in the Ts65Dn mouse model of down syndrome.
Stagni F; Magistretti J; Guidi S; Ciani E; Mangano C; Calzà L; Bartesaghi R
PLoS One; 2013; 8(4):e61689. PubMed ID: 23620781
[TBL] [Abstract][Full Text] [Related]
9. Prenatal pharmacotherapy rescues brain development in a Down's syndrome mouse model.
Guidi S; Stagni F; Bianchi P; Ciani E; Giacomini A; De Franceschi M; Moldrich R; Kurniawan N; Mardon K; Giuliani A; Calzà L; Bartesaghi R
Brain; 2014 Feb; 137(Pt 2):380-401. PubMed ID: 24334313
[TBL] [Abstract][Full Text] [Related]
10. Early pharmacotherapy restores neurogenesis and cognitive performance in the Ts65Dn mouse model for Down syndrome.
Bianchi P; Ciani E; Guidi S; Trazzi S; Felice D; Grossi G; Fernandez M; Giuliani A; Calzà L; Bartesaghi R
J Neurosci; 2010 Jun; 30(26):8769-79. PubMed ID: 20592198
[TBL] [Abstract][Full Text] [Related]
11. The polyphenols resveratrol and epigallocatechin-3-gallate restore the severe impairment of mitochondria in hippocampal progenitor cells from a Down syndrome mouse model.
Valenti D; de Bari L; de Rasmo D; Signorile A; Henrion-Caude A; Contestabile A; Vacca RA
Biochim Biophys Acta; 2016 Jun; 1862(6):1093-104. PubMed ID: 26964795
[TBL] [Abstract][Full Text] [Related]
12. Neonatal treatment with cyclosporine A restores neurogenesis and spinogenesis in the Ts65Dn model of Down syndrome.
Stagni F; Salvalai ME; Giacomini A; Emili M; Uguagliati B; Xia E; Grilli M; Bartesaghi R; Guidi S
Neurobiol Dis; 2019 Sep; 129():44-55. PubMed ID: 31085229
[TBL] [Abstract][Full Text] [Related]
13. Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans.
De la Torre R; De Sola S; Pons M; Duchon A; de Lagran MM; Farré M; Fitó M; Benejam B; Langohr K; Rodriguez J; Pujadas M; Bizot JC; Cuenca A; Janel N; Catuara S; Covas MI; Blehaut H; Herault Y; Delabar JM; Dierssen M
Mol Nutr Food Res; 2014 Feb; 58(2):278-88. PubMed ID: 24039182
[TBL] [Abstract][Full Text] [Related]
14. Prefrontal-hippocampal functional connectivity encodes recognition memory and is impaired in intellectual disability.
Alemany-González M; Gener T; Nebot P; Vilademunt M; Dierssen M; Puig MV
Proc Natl Acad Sci U S A; 2020 May; 117(21):11788-11798. PubMed ID: 32393630
[TBL] [Abstract][Full Text] [Related]
15. Early appearance of developmental alterations in the dendritic tree of the hippocampal granule cells in the Ts65Dn model of Down syndrome.
Uguagliati B; Al-Absi AR; Stagni F; Emili M; Giacomini A; Guidi S; Nyengaard JR; Bartesaghi R
Hippocampus; 2021 Apr; 31(4):435-447. PubMed ID: 33464704
[TBL] [Abstract][Full Text] [Related]
16. Neonatal therapy with clenbuterol and salmeterol restores spinogenesis and dendritic complexity in the dentate gyrus of the Ts65Dn model of Down syndrome.
Emili M; Stagni F; Salvalai ME; Uguagliati B; Giacomini A; Albac C; Potier MC; Grilli M; Bartesaghi R; Guidi S
Neurobiol Dis; 2020 Jul; 140():104874. PubMed ID: 32325119
[TBL] [Abstract][Full Text] [Related]
17. Maternal choline supplementation improves spatial learning and adult hippocampal neurogenesis in the Ts65Dn mouse model of Down syndrome.
Velazquez R; Ash JA; Powers BE; Kelley CM; Strawderman M; Luscher ZI; Ginsberg SD; Mufson EJ; Strupp BJ
Neurobiol Dis; 2013 Oct; 58():92-101. PubMed ID: 23643842
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of Epigallocatechin-3-gallate containing supplements on correcting skeletal defects in a Down syndrome mouse model.
Abeysekera I; Thomas J; Georgiadis TM; Berman AG; Hammond MA; Dria KJ; Wallace JM; Roper RJ
Mol Nutr Food Res; 2016 Apr; 60(4):717-726. PubMed ID: 26748562
[TBL] [Abstract][Full Text] [Related]
19. Combined Treatment With Environmental Enrichment and (-)-Epigallocatechin-3-Gallate Ameliorates Learning Deficits and Hippocampal Alterations in a Mouse Model of Down Syndrome.
Catuara-Solarz S; Espinosa-Carrasco J; Erb I; Langohr K; Gonzalez JR; Notredame C; Dierssen M
eNeuro; 2016; 3(5):. PubMed ID: 27844057
[TBL] [Abstract][Full Text] [Related]
20. The flavonoid 7,8-DHF fosters prenatal brain proliferation potency in a mouse model of Down syndrome.
Stagni F; Uguagliati B; Emili M; Giacomini A; Bartesaghi R; Guidi S
Sci Rep; 2021 Mar; 11(1):6300. PubMed ID: 33737521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
